Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway
Provided By GlobeNewswire
Last update: Aug 25, 2025
- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026
- Patient dosing expected to begin in Australia in Q4 2025
Read more at globenewswire.comNYSEARCA:SER (10/24/2025, 8:04:00 PM)
5.26
+0.09 (+1.84%)
Find more stocks in the Stock Screener
